Dextran sulfate

Drug Profile

Dextran sulfate

Latest Information Update: 21 Jun 2004

Price : $50

At a glance

  • Originator Polydex Pharmaceuticals
  • Developer National Institutes of Health (USA); Polydex Pharmaceuticals
  • Class Anticoagulants; Antihyperlipidaemics; Glucans; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Cancer metastases; Ovarian cancer
  • Discontinued HIV infections

Most Recent Events

  • 21 Jun 2004 Suspended - Preclinical for Cancer metastases in Japan (unspecified route)
  • 21 Jun 2004 Suspended - Clinical-Phase-Unknown for Ovarian cancer in Japan (unspecified route)
  • 24 Sep 2002 Discontinued - Phase-II for HIV infections treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top